Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | ELANE | P08246 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.30 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26847416 | 0.83 | ELANE (0.37) | NOS1KDM4EELANEMAPTPTGS1 | |
| SCHEMBL19256889 | 0.78 | PTGS1 (0.35) | KDM4EMAPK1HSD17B10MAPTPTGS1 | |
| SCHEMBL10435591 | 0.74 | ALDH1A1 (0.35) | KDM4EMAPK1HSD17B10 | |
| SCHEMBL11577322 | 0.72 | TP53 (0.35) | KDM4EMAPK1HSD17B10MAPT | |
| SCHEMBL27748702 | 0.71 | — | — | |
| SCHEMBL9957284 | 0.71 | ALDH1A1 (0.39) | KDM4EHSD17B10MAPT | |
| SCHEMBL27872985 | 0.67 | NOS1 (0.38) | NOS1 | |
| Hydrogen Sulfide SCHEMBL27996935 | 0.65 | CA12 (0.32) | KDM4EMAPK1HSD17B10 | |
| SCHEMBL27970991 | 0.65 | NOS1 (0.37) | NOS1KDM4EMAPT | |
| SCHEMBL11337612 | 0.65 | GAA (0.53) | KDM4EMAPK1HSD17B10MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365571-A1 | COMPOUNDS AND COMPOSITIONS AS Sppl2a INHIBITORS | NOVARTIS AG (CH) | 2023-11-16 | — | — | US | disclosed |
| US-20230365571-A1 | COMPOUNDS AND COMPOSITIONS AS Sppl2a INHIBITORS | NOVARTIS AG (CH) | 2023-11-16 | — | — | US | disclosed |
| EP-2611801-B1 | HERBICIDALLY EFFECTIVE KETOSULTAMS AND DIKETOPYRIDINES | BAYER IP GMBH (DE) | 2016-05-04 | — | — | EP | disclosed |
| US-9101133-B2 | Phenyl-substituted bicyclooctane-1,3-dione-derivatives | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-08-11 | — | — | US | disclosed |
| US-9101133-B2 | Phenyl-substituted bicyclooctane-1,3-dione-derivatives | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-08-11 | — | — | US | disclosed |
| WO-2012028582-A1 | HERBICIDALLY ACTIVE KETOSULTAMS AND DIKETOPYRIDINES | BAYER CROPSCIENCE AG (DE) | 2012-03-08 | — | — | WO | disclosed |
| US-20120058893-A1 | HERBICIDALLY ACTIVE KETOSULTAMS AND DIKETOPYRIDINES | BAYER CROPSCIENCE AG (DE) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365571-A1 | COMPOUNDS AND COMPOSITIONS AS Sppl2a INHIBITORS | SPPL2A, SPPL2B, BACE1 | NOS1 4383/4885KDM4E 4701/4885MAPK1 1689/4885 |
| US-20120058893-A1 | HERBICIDALLY ACTIVE KETOSULTAMS AND DIKETOPYRIDINES | KHK, KCNA1, KCNA2 | NOS1 2188/4885KDM4E 525/4885MAPK1 1476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.